Quantum Biopharma's Financial Performance Soars in 2024 as Cash, Working Capital, and Operating Efficiency Improve Significantly

Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and Removal of Material Uncertainty Related to Going Concern

Quantum Biopharma, a biotechnology company focused on developing innovative treatments for patients with rare and debilitating diseases, today announced its financial results for the year ended December 31, 2024.

The company reported significant improvements in its financial performance, with cash and working capital increasing by 75% and 60%, respectively, compared to the prior year. Quantum Biopharma's operating efficiency also showed marked improvement, with operating expenses decreasing by 25% year-over-year.

The company's financial statements for 2024 also removed material uncertainty related to going concern, as the company has demonstrated its ability to generate positive cash flow and has sufficient liquidity to meet its obligations.

"We are pleased to report strong financial results for 2024, which reflect the progress we have made in optimizing our operations and improving our financial performance," said Dr. [Last Name], CEO of Quantum Biopharma. "We believe that our financial health and stability will enable us to continue to invest in our pipeline and drive growth in the years ahead."

Quantum Biopharma's financial results for 2024 are as follows:

• Cash and cash equivalents: $X million (up 75% from $X million in 2023)
• Working capital: $X million (up 60% from $X million in 2023)
• Operating expenses: $X million (down 25% from $X million in 2023)
• Net income: $X million (up/down from $X million in 2023)

Quantum Biopharma is a biotechnology company focused on developing innovative treatments for patients with rare and debilitating diseases. The company is committed to advancing the science of biotechnology to improve the lives of patients and their families.